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The human IFI16 gene is an interferon-inducible gene impli-
cated in the regulation of endothelial cell proliferation and tube
morphogenesis. Immunohistochemical analysis has demonstrated
that this gene is highly expressed in endothelial cells in addition to
hematopoietic tissues. In this study, gene array analysis of human
umbilical vein endothelial cells overexpressing IFI16 revealed an
increasedexpressionof genes involved in immunomodulation, cell
growth, and apoptosis. Consistent with these observations, IFI16
triggered expression of adhesion molecules such as ICAM-1 and
E-selectin or chemokines such as interleukin-8 or MCP-1. Treat-
ment of cells with short hairpin RNA targeting IFI16 significantly
inhibited ICAM-1 induction by interferon (IFN)- demonstrating
that IFI16 is required for proinflammatory gene stimulation.
Moreover, functional analysis of the ICAM-1 promoter by dele-
tion- or site-specific mutation demonstrated that NF-B is the
main mediator of IFI16-driven gene induction. NF-B activation
appears to be triggered by IFI16 through a novel mechanism
involvingsuppressionof IBmRNAandproteinexpression.Sup-
port for this finding comes from the observation that IFI16 target-
ing with specific short hairpin RNA down-regulates NF-B bind-
ing activity to its cognate DNA and inhibits ICAM-1 expression
induced by IFN-. Using transient transfection and luciferase
assay, electrophoretic mobility shift assay, and chromatin immu-
noprecipitation, we demonstrate indeed that activation of the
NF-B response is mediated by IFI16-induced block of Sp1-like
factor recruitment to the promoter of the IB gene, encoding the
main NF-B inhibitor. Activation of NF-B accompanied by
induction of proinflammatory molecules was also observed when
IB expression was down-regulated by specific small interfering
RNA, resulting in an outcome similar to that observed with IFI16
overexpression. Taken together, these data implicate IFI16 as a
novel regulator of endothelial proinflammatory activity and pro-
videnewinsights intothephysiological functionsof theIFN-induc-
ible gene IFI16.
Interferons (IFNs)2 are important regulators of viral replica-
tion, cell growth, immunomodulation, and inflammation (1, 2).
Moreover, it is nowwell accepted that IFNs play a critical role in
the pathogenesis and perpetuation of specific autoimmune dis-
eases, including systemic lupus erythematosus, autoimmune
thyroid disease, and type 1 diabetes (3).
The interferon-inducible p200 family of proteins (Ifi200 in
themouse andHIN200 in the humans) is among the numerous
gene products induced by IFNs (4–6). Recently, the Pyrin
domain, commonly found among cell death-associated pro-
teins such as Pyrin, ASC, and zebrafish caspase, and also
referred to as the PAAD/DAPIN domain (7, 8), has been found
in theN terminus ofmost Ifi200/HIN200 proteins, suggesting a
role of these proteins in inflammation and apoptosis (9, 10).
The IFI16 gene, a member of the HIN200 family (4–6), was
originally identified as a target of interferons (IFN-/ and -).
Recently, however, it has become clear that oxidative stress, cell
density, and various proinflammatory cytokines also trigger
IFI16 expression (11, 12). IFI16 expression is seen in vascular
endothelial cells from blood and lymph vessels in addition to
hematopoietic cells, suggesting a possible link to angiogenesis
and inflammation (13, 14). Consistent with this hypothesis,
expression of IFI16 in HUVEC efficiently suppressed endothe-
lial migration, invasion, and formation of capillary-like struc-
tures in vitro accompanied by inhibition of cycle progression
and arrest in the G1 phase of the cell cycle (15). Additionally,
anti-IFI16 autoantibody titers are significantly elevated in
patients with autoimmune diseases such as cutaneous systemic
sclerosis, systemic lupus erythematosus, and Sjogren syn-
drome, but not in those with other autoimmune diseases when
compared with controls (16). Taken together, these results
indicate that IFI16 may be involved in the early steps of inflam-
mation by modulating endothelial cell functions.
One of the initial key events in the endothelial response to
inflammatory stimuli is the expression of adhesion molecules
such as intercellular cell adhesion molecule (ICAM-1, VCAM-1,
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andE-selectin) andproductionof chemokines, including IL-8 and
MCP-1 (17–19). The majority of genes expressed in endo-
thelial cells in response to inflammatory mediators such as
lipopolysaccharide, IL-1, or TNF- contain functionally
important NF-B-binding sites in their promoter regions (20,
21). Moreover, inhibition of NF-B activity resulted in efficient
inhibition of endothelial cell activation (22–24). The five mem-
bers of the mammalian NF-B family, p65 (RelA), RelB, c-Rel,
p50/p105 (NF-B1), and p52/p100 (NF-B2), are present in
unstimulated cells as homo- or heterodimers bound to IB
family proteins (22–24). NF-B proteins are characterized by
the presence of a conserved 300-amino acid Rel homology
domain that is located toward theN terminus of the protein and
is responsible for dimerization, interactionwith IBs, and bind-
ing to DNA. Binding to IB prevents the NF-B-IB complex
from translocating to the nucleus, thereby maintaining NF-B
in an inactive state.
Three distinct NF-B-activating pathways have emerged,
and all of them rely on sequentially activated kinases (25–27).
The first pathway, i.e. the classical pathway, is triggered by pro-
inflammatory cytokines such as TNF- and leads to the
sequential recruitment of various adaptors, including TNF
receptor-associated death domain protein, receptor interacting
protein, and TNF receptor-associated factor 2 (TRAF2) to the
cytoplasmic membrane. This is followed by the recruitment
and activation of the IB kinase (IKK) complex, which includes
the scaffold protein NF-B essential modulator (NEMO; also
named IKK), IKK, and IKK kinases. Once activated, the
IKK complex phosphorylates on Ser-32 and Ser-36 IB, which
is subsequently ubiquitinated and then degraded via the pro-
teosome pathway. A second pathway, i.e. the alternative path-
way, is NEMO-independent and is triggered by cytokines,
including lymphotoxin b, B-cell activating factor or the CD40
ligand, and by viruses (e.g. human T-cell leukemia virus and the
Epstein-Barr virus). This pathway relies on the recruitment of
TRAF proteins to the membrane and on the NF-B-inducing
kinase (NIK), which activates an IKKhomodimer. IKK phos-
phorylates the ankyrin-containing and inhibitory molecule
p100 on specific serine residues located in both the N- and
C-terminal regions. p100 is then ubiquitinated and cleaved to
generate the NF-B protein p52 that moves as a heterodimer
with RelB into the nucleus. The third signaling pathway is clas-
sified as “atypical” because it is independent of IKK but still
requires the proteosome and is triggered by DNA-damaging
agents such as UV radiation or doxorubicin. UV radiation
induces IB degradation via the proteosome, but the targeted
serine residues are located within a C-terminal cluster that is
recognized by the p38-activated casein kinase 2 (CK2).
To add new information to the physiological role of IFI16 in
the modulation of the immune response and inflammation, we
initiated microarray analysis of IFI16-overexpressing HUVEC.
The results obtained indicate that genes involved in inflamma-
tion, cell proliferation, and apoptosis are affected by IFI16 over-
expression. In particular we demonstrate that IFI16 stimulates
the expression of proinflammatory genes, including ICAM-1,
E-selectin, IL-8, and MCP-1. ICAM-1 stimulation by IFNs
appears to depend on functional IFI16, because inhibition of its
expression by RNA interference blocks the IFN capability to
increase ICAM-1 expression. ICAM-1 induction takes place
through activation of the NF-B complex that appears to be
triggered by transcriptional suppression of the IB gene
expression. Consistent with these observations, reduction in
IB expression by RNA interference results in the same out-
come observed with IFI16 overexpression. Altogether, these
results demonstrate that IFI16 modulates the response of
proinflammatory cytokines in endothelial cells and may pro-
vide amolecular explanation for its role in the initial steps of the
autoimmune response.
EXPERIMENTAL PROCEDURES
Cells Lines and Reagents—HUVECobtained by trypsin treat-
ment of umbilical cord veins were cultured in endothelial
growth medium (EGM-2, Clonetics, San Diego) containing 2%
fetal bovine serum, human recombinant vascular endothelial
growth factor, basic fibroblast growth factor, human epidermal
growth factor, insulin growth factor (IGF-1), hydrocortisone,
ascorbic acid, heparin, gentamycin, and amphotericin B (1
g/ml each) and were seeded into 100-mm culture dishes
coated with 0.2% gelatin. Experiments were performed with
cells at passage 2–6. Human embryo kidney 293 cells (HEK-
293) (Microbix Biosystems Inc.) were cultured in minimum
Eagle’s medium (Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen), 2 mM glutamine, 100 units of peni-
cillin per ml, and 100 g per ml of streptomycin sulfate. Cells
were kept in logarithmic growth phase by 1 citric saline
detachment and reinoculation every 2–4 days. Interferon-
and TNF- were the generous gifts of Gianni Garotta, Geneva,
Switzerland, and Tiziana Musso, Turin, Italy, respectively.
RecombinantAdenovirus Preparations andHUVEC Infection—
The pAC-CMV IFI16, containing the human IFI16 cDNA
linked to a FLAG tag at the N terminus, was cotransfected
together with pJM17 into human embryonic kidney 293 cells as
described previously (11). After several rounds of plaque puri-
fication, the adenovirus containing the IFI16 gene (AdVIFI16)
was amplified on 293 cell monolayers and purified from cell
lysates by banding twice on CsCl gradients. Desalting was per-
formed using G-50 columns (Amersham Biosciences), and
viruses were frozen in PBS, 10% glycerol at80 °C. The infec-
tious titers (PFU) were determined by a standard plaque assay
on 293 cell monolayers (11). The physical particles of the vector
preparations were measured by spectrophotometry (28), and
our viral preparations showed a 1:10–1:20 ratio between PFU
and physical particles. Endotoxin contaminations were
excluded by E-Toxate kit (Sigma) (sensitivity  1.4 pg/ml).
Recombinant AdVIFI16 was tested for IFI16 expression by
Western blotting, using an anti-FLAG antibody (Sigma). For
cell transduction, pre-confluent HUVEC were washed once
with PBS and incubated with AdVIFI16 or AdVLacZ (used as a
control) at a multiplicity of infection (m.o.i.) of 300 in EGM.
After 60 min at 37 °C, the virus was washed off, and fresh
medium was added. Cells were cultured for 36 h before use in
the experiments.
For IFI16 interference the pAC-CMV shRNA-IFI16, con-
taining the short hairpin RNA sequence targeting the human
IFI16 gene mRNA (shRNAIFI16) (5-CCG TCA GAA GAC
CAC AAT CTA CTT CAA GAG AGT AGA TTG TGG TCT
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TCT GAT TTT TTG GAA A-3), or the pAC-CMV shRNA-
SCRAMBLED (shRNASCR), containing a scrambled human
IFI16 gene shRNA sequence (5-CCG GCA CAG TCA CAA
CAA ATC TTT CAA GAG AAG ATT TGT TGT GAC TGT
GCT TTT TTG GA AA-3), were cotransfected with pJM17
into 293 cells. After several rounds of plaque purification,
recombinant adenoviruseswere amplified on 293 cellmonolay-
ers and purified to homogeneity as before. PFU were assessed
for virus titers on the 293 complementing cell line with agar
overlay. Recombinant AdVshRNAIFI16 was tested for IFI16
knockdown by Western blotting. For cell transduction,
HUVEC were washed once with PBS and incubated with
AdVshRNAIFI16 or AdVshRNASCR at an m.o.i. of 300 in
EGM.After 2 h at 37 °C, the viruswaswashed off, and cells were
treated as indicated. For IB interference, the adenoviral
human IB siRNA recombinant virus (AdVshRNAIB) con-
taining the short hairpin RNA sequence targeting the human
IB gene mRNA was purchased from Imgenex (San Diego,
CA) and used according to themanufacturer’s instruction at an
m.o.i. of 1000.
Microarray and Data Analysis—Total RNA was extracted
from HUVEC cultured at subconfluence and infected with
AdVIFI16 or AdVLacZ for 6 h or 24 h. RNA pooled from dif-
ferent cultures was used as a template for biotinylated probe
synthesis. Total RNAs were quality-controlled and quantified
on the Bioanalyzer 2100 (Agilent). For gene expression profil-
ing on Beadchips from Illumina, reverse transcription, double-
stranded cDNA, and biotinylated cRNA synthesis were carried
out according to standard Illumina protocols, using the “Illu-
mina RNA amplification kit” (Ambion) and biotin-16 UTP
(RocheApplied Science). Briefly, 500 ng of total RNAwere used
for reverse transcription to synthesize double-stranded cDNA.
The cDNA was used for in vitro transcription to obtain biotin-
ylated cRNA, followed by a purification step. Subsequently, 550
ng of biotinylated cRNA, resuspended in Hyb E1 buffer, form-
amide, and RNase-freewater, were denatured at 65 °C for 5min
and hybridized for 16 h at 55 °C on Ilumina “Human Sampler”
bead arrays, exploring 516 genes. Hybridized bead arrays were
thenwashed three timeswith E1BCbuffer (Illumina), oncewith
100% EtOH, blocked using blocking E1 buffer (Illumina), and
stained with streptavidin-Cy3 (2 l per chip of 1 mg/ml stock,
from Amersham Biosciences). After the final washing and dry-
ing, bead arrays were scanned on a GenePix Personal 4100A
microarray reader (Axon). Imageswere processedwith theBea-
darray Studio software (Illumina) to extract signal intensities
for each bead type in each experiment and export them to a
tab-delimited text file. Statistical analysis and selection of reg-
ulated genes was carried out using Excel (Microsoft). We
defined two criteria for selecting regulated genes as follows: (a)
genes that were regulated more than 2-fold in both replicates
(32 genes); (b) genes that were regulated by average at least
1.4-fold plus 2 standard deviations (45 genes). The first
approach allowed capturing genes with greater response, and
the second allowed identifying genes with smaller, but consist-
ent, response. In total, we selected 55 genes, of which 22 passed
both tests.
Real Time RT-PCR Analysis—RT-PCR analysis was per-
formed on anMx 3000 PTM (Stratagene) using the SYBRGreen
I dye (Invitrogen) as a nonspecific PCR product fluorescence
label. Total cellular RNAwas isolated using the Eurozol reagent
(EurocloneLtd.). RNA (1g)was then retrotranscribed at 42 °C
for 60 min in PCR buffer (1.5 mM MgCl2) containing 5 M
random primers, 0.5 mM dNTP, and 100 units of Moloney
murine leukemia virus reverse transcriptase (Ambion) in a final
volume of 20l. cDNAs (2l) or water as control was amplified
in duplicate by real time RT-PCR using the Brilliant SYBR
GreenQPCRmastermix (Stratagene) in a final volume of 25l.
Primer sequences were as follows: IFI16 (sense, 5-ACT GAG
TAC AAC AAA GCC ATT TGA-3; antisense, 5-TTG TGA
CATTGTCCTGTCCCCAC-3); ICAM-1 (sense, 5-CAACCG
GAAGGTGTATGAAC-3; antisense, 5-CAGCGTAGGGTA
AGG TTC-3); V-CAM1 (sense, 5-CAT GGA ATT CGA ACC
ACA-3; antisense, 5-GAC CAA GAC GGT TGT ATC GG-3);
BAD (sense, 5-CAT TGA GCC GAG TGA GCA GG-3; anti-
sense, 5-TCG TCA CTC ATC CTC CGGAG-3); UCP3 (sense,
5-CGT GGT GAT GTT CGT AAC CTA TG-3; antisense,
5-CGG TGA TTC CCG TAA CAT CTG-3); CDC25a
(sense, 5-CTC CTC CGAGTC AAC AGA TT-3; antisense,
5-CAG AGT TCT GCC TCT GTG TG-3); SSTR1 (sense,
5-GGC GAA ATG CGT CCC AG-3; antisense, 5-CGG
AGT AGA TGA AAG AGA TCA GGA-3); CCR4 (sense,
5-CCT CAG AGC CGC TTT CAG A-3; antisense, 5-GCC
TTG ATG CCT TCT TTG GT-3); E-Selectin (sense, 5-CTC
TGA CAG AAG AAG CCA AG-3; antisense, 5-ACT TGA
GTC CAC TGA AGT CA-3); MCP-1 (sense, 5-TCC TGT
GCCTGCTGCTGATAGC-3; antisense, 5-TTCTGAACC
CAC TTC TGC TTG G-3); IL-8 (sense, 5-ATG ACT TCC
AAG CTG GCC GTG GCT-3; antisense, 5-TCT CAG CCC
TCT TCA AAA ACT TCT C-3); PAI-1 (sense, 5-TGC TGG
TGA ATG CCC TCT ACT-3; antisense, 5-CGG TCA TTC
CCA GGT TCT CTA-3); PTX-3 (sense, 5-TGG CTG CCG
GCA GGT; antisense, 5-TCC ACC CAC CAC AAA CAC
TAT-3); and -actin (sense, 5-GTT GCT ATC CAG GCT
GTG-3; antisense, 5-TGT CCA CGT CAC ACT TCA-3).
Following an initial denaturing step at 95 °C for 2 min to acti-
vate 0.75 units of Platinum TaqDNA polymerase (Invitrogen),
the cDNAs were amplified for 30 cycles (95 °C for 1 min, 58 °C
for 1 min, and 72 °C for 1 min). For quantitative analysis, semi-
logarithmic plots were constructed of  fluorescence versus
cycle number, and a threshold was set for the changes in fluo-
rescence at a point in the linear PCR amplification phase (Ct).
TheCt values for each genewere normalized to theCt values for
-actinwith theCt equation. The level of target RNA, normal-
ized to the endogenous reference and relative to the mock-
infected and untreated cells, was calculated by the comparative
Ct method with the 2Ct equation.
Plasmids and Transfection Assays—Reporter luciferase vec-
tors for human full-length ICAM-1promoter pIC1352 (1352/
1) and the relevant mutant constructs pIC339 (339/1),
pIC135 (135/1), and pIC135 (AP2) have been described
previously (29). To derive ICAM-1 promoter with mutated
NF-B-binding sites, the sequence of these sites was modified
by two consecutive rounds of site-directed mutagenesis
(QuikChange XL site-directed mutagenesis kit; Stratagene).
The two NF-B recognition sites were abrogated and changed
to unique restriction sites (187 BamHI, and 491 KpnI) in
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the plasmid pIC1352 (mut2NF-B). In the plasmid pIC339
(mutNF-B) the 187 NF-B-binding site was mutated and
changed with BamHI restriction site. The correctness of the
introduced mutations was confirmed by sequencing the
derived constructs. The pGL2-ICAM-1 construct, spanning
137 nucleotides before the translation start site and carrying
two Ets-responsive sites, pGL2-ICAM-1/Mut117, pGL2-
ICAM-1/Mut97, and pGL2-ICAM-1/Mut117–97, the specific
mutants for one or both Ets sites, respectively, have been
described previously (30). The 0.4SK-pGL3 Luc, obtained by
subcloning the 0.4-kb fragment of the IB promoter, and the
relevant mutant constructs, mutkB1, mutSp1, and mutkB1/
Sp1, have been described previously (31). For transfection
experiments, HUVEC cells grown to subconfluencewere trans-
fected with 2 g of the reporter vector of interest that was
added to serum-free EGM-2, mixed with 6 l of Reagent Plus
and 3l of Lipofectamine (Invitrogen), and incubated for 2 h at
37 °C.After 4 h, themediumwas replacedwith EGM-2medium
containing 2% fetal bovine serum. Twenty four hours later, cells
were infectedwithAdVIFI16 orAdVLacz (at anm.o.i. of 300) or
mock-infected. After 24 h of incubation, chemiluminescence
was measured using the Lumino luminometer (Stratec Bio-
medical Systems, Birkenfeld, Germany). Reporter gene activity
was normalized to the amount of plasmidDNA introduced into
the recipient cells measured by real time PCR with appropriate
luciferase-actin primers.
Nuclear Extract Isolation and Electrophoretic Mobility Shift
Assay (EMSA)—HUVEC were plated at a density of 3  105
cells/100-mm diameter dish and after 72 h infected with
AdVIFI16, AdVLacz, or mock-infected. At the indicated times
post-infection (p.i.), cells were washed in cold PBS, harvested,
and centrifuged to collect the pellet. The pellets were then incu-
bated for 15 min on ice with a cytoplasmic isolation buffer (10
mMHEPES (pH 7.6), 60mMKCl, 1mMEDTA, 1mMdithiothre-
itol, 1 mM phenylmethylsulfonyl fluoride, 0.5% Nonidet P-40,
protease and phosphatase inhibitormixture (Sigma)). The sam-
ples were centrifuged, and the nuclear pellets were then col-
lected by removing the supernatant containing the cytoplasmic
extract, washed in cytoplasmic isolation buffer without Non-
idet P-40, centrifuged, and incubated for 10 min on ice with a
nuclear isolation buffer (20 mM Tris-HCl (pH 8.0), 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethyl-
sulfonyl fluoride, 25% glycerol, protease inhibitor mixture
(Sigma)). After centrifugation, supernatants containing the
nuclear extracts were collected and stored at 70 °C. EMSA
was performed as described previously (32). Briefly, nuclear
extracts (15 g of proteins) were incubated in a binding buffer
(10 mM Tris-HCl (pH 7.9), 50 mM NaCl, 0.5 mM EDTA, 1 mM
dithiothreitol, 7.5 mM MgCl2) with 1 g of poly(dI-dC) (GE
Healthcare) and the 32P-labeled double-strandedNF-B, AP-1,
and Sp1 consensus oligonucleotides (Promega). The oligonu-
cleotide probe was labeled with [-32P]ATP (Amersham Bio-
sciences) and T4 polynucleotide kinase according to the man-
ufacturer’s protocol, and finally column-purified on G-25
Sephadex (Bio-Rad). Complexes were analyzed by nondenatur-
ing 4% PAGE, dried, and detected by autoradiography.
Immunoblotting—Whole-cell protein extracts were pre-
pared by resuspending pelleted cells in lysis buffer containing
125 mM Tris-Cl (pH 6.8), 1% SDS, 20 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 4 g/ml leupeptin, 4 g/ml
aprotinin, 1 g/ml pepstatin. After a brief sonication, soluble
proteins were collected by centrifugation at 15,000 g. Super-
natants were analyzed for protein concentration with a Dc pro-
tein assay kit (Bio-Rad) and stored at 70 °C in 10% glycerol.
Proteins were separated by SDS-PAGE and then transferred to
Immobilon-P membranes (Millipore). Filters were blocked in 5%
nonfat dry milk in 10 mM Tris-Cl (pH 7.5), 100 mM NaCl, 0.1%
Tween 20 and immunostained with the rabbit anti-IFI16 Ab
(diluted 1:2000), the rabbit anti-IB polyclonal antibody (Santa
Cruz Biotechnology) (diluted 1:500), the rabbit anti-p50 poly-
clonal antibody (Santa Cruz Biotechnology) (diluted 1:300), the
mouse anti-p65mAb (Santa Cruz Biotechnology) (diluted 1:500),
the mouse anti-IKK2 mAb (Pharmingen) (diluted 1:1000), or the
mouse anti-actin mAb (Chemicon) (diluted 1:4000). Immuno-
complexes were detected with either sheep-anti mouse Ig Ab or
donkey anti-rabbit Ig Ab conjugated to horseradish peroxidase
(Amersham Biosciences) and visualized by enhanced chemilumi-
nescence (Super Signal, Pierce).
IKK Kinase Assay—HUVEC cells were plated at a density of
3  105 cells/100-mm diameter dish and after 72 h infected
with AdVIFI16, AdVLacZ, or mock-infected. At the indicated
times p.i., whole-cell lysates were prepared as described previ-
ously (32, 33). Briefly, cells were resuspended in WCE lysis
buffer (20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 0.25% Triton
X-100, 1 mM EDTA, 1 mM EGTA, 10 mM -glycerophosphate,
10 mM NaF, 10 mM 4-nitrophenyl phosphate, 300 M Na3VO4,
1 mM benzamidine, 2 M phenylmethylsulfonyl fluoride, 1 mM
dithiothreitol, protease inhibitor mixture (Sigma)) and gently
rotated at 4 °C for 45 min; the lysates were centrifuged at
15,000 g for 10min at 4 °C and then stored at80 °C. 2g of
anti-IKK1mAb (Pharmingen) was added at 4 °C for 2 h. Protein
A-Sepharose (GE Healthcare) was then added, and samples
were incubated at 4 °C for a further 2 h. The immunoprecipi-
tates were washed three times in WCE buffer and twice in
Kinase Reaction buffer (20 mM HEPES (pH 7.7), 2 mM MgCl2,
10 mM -glycerol phosphate, 10 mMNaF, 10mM 4-nitrophenyl
phosphate, 300 M Na3VO4, 1 mM benzamidine, 2 M phenyl-
methylsulfonyl fluoride, 1mM dithiothreitol, protease inhibitor
mixture (Sigma)), and endogenous IKKactivitywas determined
using GST-IB-(1–54) as a substrate. Kinase activity was
assayed in 50 l of KR buffer with 10 M ATP and 5 Ci of
[-32P]ATP (Amersham Biosciences) at 30 °C for 30 min in the
presence of GST-IB. After incubation samples were sepa-
rated by SDS-PAGE, transferred to Immobilon-P membranes
(Millipore), and processed for autoradiography and immuno-
blotting. Signals were quantitated with a densitometer. Immu-
noblotting analysis with anti-IKK1 mAb was performed as
immunoprecipitation recovery control.
Chromatin Immunoprecipitation Assay—Cells were incu-
bated for 10 min at room temperature with PBS containing 1%
formaldehyde. Formaldehyde cross-linking was stopped by
adding glycine to a final concentration of 125 mM for 5 min at
room temperature. Cells were then washed with ice-cold PBS
containing protease inhibitors and 1 mM phenylmethylsulfonyl
fluoride and resuspended in RIPA buffer (150 mM NaCl, 1%
Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl
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(pH 8), 5 mM EDTA) containing protease inhibitors for 20 min
on ice. Samples were sonicated to reduce the DNA length to
200–600 bp, and cellular debris was removed by centrifuga-
tion. Before ChIP, the samples were precleared with protein
G-agarose/carrier DNA mixture. The supernatant was recov-
ered andused directly for immunoprecipitation experiments by
incubation with appropriate antibodies for 60 min at 20 °C and
then incubated for 2 h at 4 °C with protein G-agarose/carrier
mixture. After immunoprecipitation, beads were collected and
sequentially washed twice with 1 ml each of the following buff-
ers: low salt wash buffer (150 mM NaCl, 1% Nonidet P-40, 0.5%
deoxycholate, 0.1% SDS, 50mMTris-HCl (pH 8), 5 mM EDTA),
high salt wash buffer (500 mM NaCl, 1% Nonidet P-40, 0.5%
deoxycholate, 0.1% SDS, 50mMTris-HCl (pH 8), 5 mM EDTA),
LiCl wash buffer (0.5% Nonidet P-40, 0.5% deoxycholate, 250
mM LiCl, 10 mM Tris-HCl (pH 8), 1 mM EDTA), and TE buffer.
DNA-protein cross-links were reversed by incubation at 65 °C
with 1% SDS/TE buffer. The samples were then digested with
proteinase K, and DNA was recovered by phenol/chloroform/
isoamyl alcohol extraction and precipitated with 2 volumes of
ethanol and then resuspended in TE/RNase A buffer and incu-
bated for 1 h at 37 °C. The input lysates were processed as
above. DNA was analyzed by quantitative real time PCR using
primer for the human IB promoter. The primers sequence
used are 5-CTA GCA GAG GAC GAA GCC AGT-3 and
5-CGC CTA TAA ACG CTG GCT G-3. The amount of the
DNA precipitated by the antibody was normalized to the total
inputDNA thatwas not subjected to immunoprecipitation.We
assigned the value 1 to the normalized IB level on AdVLacZ-
infected cells immunoprecipitated with unrelated antibody.
NF-B Immunofluorescence Studies—HUVEC were seeded
onto glass coverslips pretreated with 0.1% polylysine in 24-well
plates and infected with AdVIFI16 or AdVLacZ at an m.o.i. of
300 or treated with TNF- (50 ng/ml) for 24 h. The cells were
then fixed in 4% phosphate-buffered paraformaldehyde for 10
min at 4 °C, permeabilizedwith the addition of phosphate-buff-
ered 0.1% Triton X-100 (w/v) for 5 min at room temperature,
and then incubated in PBS containing 1% bovine serum albu-
min (w/v, blocking solution) for 30 min. Incubation of the cells
was done with either rabbit anti-human NF-B p65 polyclonal
antibodies (sc-372, Santa Cruz Biotechnology) or IFI16 mAb
(1:250 dilution in blocking solution) (Santa Cruz Biotechnol-
ogy) for 1 h at room temperature. This was followed by incuba-
tion with goat anti-rabbit antibodies (1:200 dilution in blocking
solution) conjugated to FITC or goat anti-mouse conjugated to
Texas Red (1:200) for 45 min at room temperature. Finally, the
coverslips were mounted and sealed for examination under a
confocal microscope (DMIRE2, Leica Microsystem, Heidel-
berg, Germany).
Flow Cytometry and Antibodies—HUVEC cultured in
60-mm dishes (104 cell/cm2) were infected with AdVLacZ,
AdVshRNAIFI16, or AdVshRNASCR or mock-infected. Sixty
h.p.i cells were treated with IFN- (2000 units/ml) and 36 h
later were collected for ICAM-1 cell surface staining. Cells were
preincubatedwithhumanserumfor15minat4 °C toblockunspe-
cific binding, washed twice with 0.1% NaN3, 0.2% bovine serum
albumin in PBS, and incubated for 30 min at 4 °C with anti
ICAM-1 mAb (Chemicon) followed by FITC-labeled goat anti-
mouse IgG. Negative controls consisted of isotype-matched con-
trolmAb. Labeled cellswere analyzedusingFACScan flowcytom-
eter (BD Biosciences). Each analysis represented the results from
at least 104 events.
RESULTS
IFI16 OverexpressionModifies the Gene Expression Profiles of
Endothelial Cells—To investigate the effects of IFI16 overex-
pression on the expression of a panel of endothelial cell genes,
HUVEC cells were infected with AdVIFI16 or AdVLacZ at an
m.o.i. of 300 as described previously (11). As shown in Fig. 1A,
IFI16 protein expression started to moderately increase at
6 h.p.i., continued to increase at 12 h.p.i., and peaked at 24 h.p.i.
A similar pattern of IFI16 expression was observed when pro-
tein extracts from IFN--treated HUVEC (2000 IU/ml) were
analyzed (Fig. 1B). According to the kinetics results of IFI16
expression cellularmRNAwas harvested at both 6 and 24 h.p.i.,
and RNA samples were analyzed using Sentrix human sampler
arrays. This probe set is designed to detect 516 unique human
transcripts divided into 7 housekeeping genes, 55 genes
involved in apoptosis regulation, 38 in drugs metabolism, 82 G
protein-coupled receptors, 312 in cell cycle regulation and
oncogenesis, and 137 in immune system regulation. The signals
were normalized to those obtained from cells expressing the
control LacZ protein. Overall, the expression of 55 cellular
mRNA (10.6% of the total number of mRNAs examined) was
altered by IFI16 overexpression. As shown in Table 1, these
genes can be grouped in five clusters as follows: 1) those genes
exemplified by MDM2 and KPNA1 that were found increased
FIGURE1.EffectsofadenovirusinfectionorIFN-treatmentonIFI16expres-
sion. A, kinetics of adenovirus-mediated IFI16 overexpression. HUVECs were
infectedwithAdVIFI16, AdVLacz (m.o.i. of 300PFU/cell), ormock-infected. At the
indicated timespost-infection, total cell extractswerepreparedandsubjected to
immunoblotting analysis with anti-IFI16 polyclonal Ab. Actin immunodetected
with a mAb served as internal control. B, induction of IFI16 mediated by IFN-.
HUVECs were stimulated with IFN- (2000 IU/ml). At the indicated times after
IFN- treatment total cell extractswereprepared and subjected to immunoblot-
ting analysis with anti-IFI16 Ab. Actin served as an internal control for sample
loading.
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at 6 h.p.i. and then returned to the basal level within 24 h; 2)
those genes like IL7R and CD28 that were increased at 6 h.p.i.
but were decreased at 24 h.p.i.; 3) those genes like ENG and
EDN1 whose expression is decreased at 6 h.p.i. and then
returned to the basal level at 24 h.p.i.; 4) those genes like
ICAM-1 and CCR4 that started to increase at 6 h.p.i. and
remained at an elevated level at 24 h.p.i.; and finally, 5) genes
like IL2RB that were unaffected at 6 h.p.i. but decreased at
24 h.p.i. Some of the genes identified such as MDM2 (HDM2)
were previously reported to be up-regulated by IFI16 (34), thus
confirming the validity of our gene array analysis. Interestingly,
as shown in Table 1, some IFI16 up-regulated genes belong to
the panel of genes involved in immune system regulation and
apoptosis regulation. In fact, ICAM-1, MIF, and CCR4 have
been implicated in the inflammatory response of endothelial
cells tomicrobial infections, oxidative stress, vascular disorders
and tumors. Real time RT-PCR analysis (Fig. 2A) confirmed the
gene array data indicating that IFI16 overexpressionmodulates
the expression of endothelial genes implicated in inflammation,
cell growth, and apoptosis.
Among the genes identified by gene array analysis, we found
that IFI16 overexpression resulted in increased ICAM-1 up-
regulation. Because we have previously observed that IFI16
expression is stimulated when endothelial cells are exposed to
oxidative stress or proinflammatory cytokines (11, 12), this
finding prompted us to analyze if other proinflammatory mol-
ecules are induced as well. To address this hypothesis, HUVEC
were infected with AdVIFI16 or AdVLacZ (m.o.i. of 300) and
18 h.p.i. mRNA were purified and analyzed by real time RT-
PCR with appropriate primers. As shown in Fig. 2B, levels of
TABLE 1
IFI16-mediated gene expression changes in endothelial cells
GPCR indicates G protein-coupled receptors.
Gene category Gene symbol Description Fold induction 6 h Fold induction 24 h
Cancer TYR Homo sapiens tyrosinase 1.23 0.105
KPNA1 H. sapiens karyopherin 1 1.49 0.105
CDC25A H. sapiens cell division cycle 25A 2.66 0.11
MGST1 H. sapiensmicrosomal glutathione S-transferase 1 0.93 0.14
PIM1 H. sapiens pim-1 oncogene 0.905 0.285
CGA H. sapiens glycoprotein hormones 1.45 0.385
LDLR H. sapiens low density lipoprotein receptor 1.35 0.5
MTHFD2 H. sapiensmethylene tetrahydrofolate dehydrogenase 1.95 0.59
ENG H. sapiens endoglin 1.03 0.25
GPX1 H. sapiens glutathione peroxidase 1 0.63 0.395
SOD1 H. sapiens superoxide dismutase 1 0.06 0.57
SSTR1 H. sapiens somatostatin receptor 1 0.45 3.17
SFTPD H. sapiens surfactant, pulmonary-associated protein D 0.75 2.845
HSD3B1 H. sapiens hydroxy--5-steroid dehydrogenase, 3- and steroid -isomerase 1 0.74 2.115
HMOX1 H. sapiens heme oxygenase (decycling) 1 0.085 0.76
IL2RB H. sapiens interleukin 2 receptor 0.215 3.39
UCP3 H. sapiens uncoupling protein 3 0.225 2.33
FSHR H. sapiens follicle-stimulating hormone receptor 1.19 1.45
CYP1A1 H. sapiens cytochrome P450 1.275 1.86
IL1RN H. sapiens interleukin 1 receptor antagonist 1.485 1.825
EDN1 H. sapiens endothelin 1 1.825 0.865
MKRN2 H. sapiensmakorin, ring finger protein, 2 1.135 0.62
CDKN1B H. sapiens cyclin-dependent kinase inhibitor 1B (p27, Kip1) 1.485 0.975
XRCC1 H. sapiens x-ray repair complementing defective repair in Chinese hamster cells 1 1.17 1.035
MPO H. sapiensmyeloperoxidase 1.92 1.27
LPL H. sapiens lipoprotein lipase 1.355 1.58
Immuno STAT2 H. sapiens signal transducer and activator of transcription 2 1.57 0.04
MAP2K1 H. sapiensmitogen-activated protein kinase kinase 1 1.015 0.13
ICAM1 H. sapiens intercellular adhesion molecule 1 0.935 2.315
CD81 H. sapiens CD81 antigen 1.595 0.105
PCP4 H. sapiens Purkinje cell protein 4 0.36 1.925
FAF1 H. sapiens Fas (TNFRSF6)-associated factor 1 1.36 0.835
CD28 H. sapiens CD28 antigen (Tp44) 1.695 1.735
CSF3R H. sapiens colony-stimulating factor 3 receptor (granulocyte) 1.075 0.535
GADD45A H. sapiens growth arrest and DNA damage-inducible,  1.17 0.295
PCNA H. sapiens proliferating cell nuclear antigen 1.28 0.085
MIF H. sapiensmacrophage migration inhibitory factor 0.26 1.05
CDKN2A H. sapiens cyclin-dependent kinase inhibitor 2A 0.64 1.31
JAK3 H. sapiens Janus kinase 3 (a protein-tyrosine kinase, leukocyte) 0.665 0.635
IL7R H. sapiens interleukin 7 receptor 1.85 1.515
CCR4 H. sapiens chemokine (C-C motif) receptor 4 1.42 1.61
Apoptosis RPA3 H. sapiens replication protein A3, 14 kDa 1.135 0.05
TNFSF4 H. sapiens tumor necrosis factor (ligand) superfamily 0.145 0.815
MDM2 H. sapiensMdm2 4.6 0
BAD H. sapiens BCL2-antagonist of cell death 1.15 1.35
GPCR HRH4 H. sapiens histamine receptor H4 0.65 0.325
MC5R H. sapiensmelanocortin 5 receptor 1.405 0.23
CHRM1 H. sapiens cholinergic receptor, muscarinic 1 1.37 1.33
NMU2R H. sapiens neuromedin U receptor 2 1.2 0.795
DRD2 H. sapiens dopamine receptor D2 1.375 0.58
Drug metabolism UCHL5 H. sapiens ubiquitin C-terminal hydrolase L5 0.955 0.05
NAT1 H. sapiens N-acetyltransferase 1 (arylamine N-acetyltransferase) 0.325 1.825
PON1 H. sapiens paraoxonase 1 1.505 0.86
Miscellaneous UBC H. sapiens ubiquitin C 1.605 0.275
EEF1A1 H. sapiens eukaryotic translation elongation factor 1 1 1.72 0.03
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mRNA corresponding to ICAM-1, E-selectin, VCAM, IL8, and
MCP-1 from AdVIFI16-infected cells were increased 7.8-, 5.5-,
3.8-, 4.3-, and 2.5-fold, respectively, compared with the same
mRNA from AdVLacZ-infected HUVEC. By contrast, no
induction of mRNA corresponding to PAI-1 and PTX-3 was
observed, suggesting selectivity in the IFI16 activity.
FIGURE2.Real timePCRanalysisofAdVIFI16-infectedHUVEC.A, total cellular RNAwasextracted fromHUVEC infectedwithAdVIFI16orAdVLacZat anm.o.i.
of 300 for 6 and 24 h and reverse-transcribed into cDNA, and the expression levels of indicated genes were assessed by real time PCR. The ratio of AdVIFI16/
AdVLacZ infectedand standardized toglyceraldehyde-3-phosphatedehydrogenaseas an internal control is shown. Thedata shownare thevalues (S.E.) from
three independent experiments. B, total cellular RNA was extracted from HUVEC infected with AdVIFI16 or AdVLacZ at an m.o.i. of 300 for 24 h and reverse-
transcribed into cDNA, and the expression levels of indicated geneswere assessed by real time PCR. The ratio of AdVIFI16/AdVLacZ infected and standardized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control is shown. The data shown are the values (S.E.) from three independent
experiments.
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IFI16 Is Necessary and Sufficient for ICAM-1 Induction by
IFN-—The above results suggest a role of IFI16 in the up-reg-
ulation of proinflammatory genes in endothelial cells. To eval-
uate the role of IFI16 in the stimulation of ICAM-1 expression
in a more physiological setting, we next investigated the func-
tional relevance of endogenous IFI16 in the IFN--mediated
ICAM-1 up-regulation (35, 36). To this end, endogenous IFI16
expression was inhibited before IFN- treatment by transduc-
tion of HUVEC cells with an AdVshRNAIFI16 that produces a
specific shRNA targeted to IFI16. As shown in Fig. 3A, the
shRNA treatment could effectively block IFI16 induction by
IFN- at 96 h.p.i. We then measured ICAM-1 induction in the
presence of IFN-. Upon treatment with 2000 IU/ml IFN- the
percentage of positive cells increased from 60 to 94% with a
mean fluorescence intensity ranging from 53 to 145, respec-
tively (Fig. 3B). Consistentwith the results of real timeRT-PCR,
IFI16 overexpression triggered an increase of ICAM-1-positive
cells from 56% (AdVLacZ) to 93% (AdVIFI16) with a mean flu-
orescence intensity ranging from 56 to 143, respectively. Next,
we analyzed the efficacy and specificity of shRNA to negatively
interfere with IFN--induced ICAM-1 expression in HUVEC.
For that, prior to IFN- stimulation, we infectedHUVEC either
with IFI16 shRNA or with a scrambled shRNA serving as
sequence-unrelated control. Infection with AdVshRNASCR
hardly affected the extent of ICAM-1 expression upon IFN-
treatment (92% compared with 94% with a mean fluorescence
density of 130 compared with 145). By contrast, infection with
IFI16 shRNA (AdVshRNAIFI16) significantly decreased the
percentage of stimulated ICAM-1 positive cells to 48% com-
pared with HUVEC infected with AdVshRNASCR and treated
with IFN-. The decrease in ICAM-1 positive cells was paral-
leled by a reduction of the mean fluorescence density from 130
(AdVshRNASCR) to 58 (AdVshRNAIFI16) (Fig. 3B). Taken
together, these results demonstrate that in cells exposed to
IFN-, endogenous IFI16 is the main mediator of ICAM-1
stimulation. Thus, these results underscore the potential phys-
iological role of IFI16 in the regulation of proinflammatory
genes in endothelial cells.
Identification of IFI16-responsive Elements on ICAM-1
Promoter—Next, to identify the responsive elements to IFI16, a
functional analysis of the ICAM-1 gene promoter was per-
formed. Indicator plasmids containing ICAM-1 promoter seg-
ments progressively deleted from the 5 end were employed.
Transient transfection assays were performed with pIC1352
(1352/1); pIC339 (339/1), which contains the proximal
NF-B-binding site and the GAS site of the ICAM-1 promoter;
pIC135 (135/1), which contains the GAS site but not the
proximal NF-B site; and pIC135 (AP2), generated by the jux-
taposition of aDNA segment spanning positions135 to105
with a fragment spanning positions 38 to 1, and thus con-
taining the two Ets sites plus the TATA box (29, 30). As shown
in Fig. 4A, the stimulation observed in AdVIFI16 HUVEC
decreased when the DNA segment containing the 5-flanking
region of the ICAM-1 gene was progressively shortened as in
pIC339 (5-fold stimulation), pIC135 (2.5-fold), and pIC135
(AP2) (2-fold). These results indicate thatmost of the ICAM-1
gene promoter responsiveness (about 75%) to IFI16 expression
was associated with nucleotide sequences upstream from135
nucleotides. There have been some reports that ICAM-1 induc-
tion by IFN- requiresNF-B activation (35, 36) thus suggesting a
possible role of NF-B-binding sites in transcriptional regulation
of ICAM-1promoterby IFI16.Tostudy further the involvementof
NF-B pathway in IFI16-induced ICAM-1 expression, transient
transfection assays were performed using the human ICAM-1
promoter-luciferase constructs, pIC1352mut2NF-B, which
contains full-length human ICAM-1 promoter bearing two
mutated B sites or the pIC339mutNF-B, which contains only
one mutated B site at the position187. As shown in Fig. 4A,
mutation of both B sites in the full-length ICAM-1 promoter
or mutation of the single B site in the pIC339 construct
strongly decreases the capability of IFI16 to trigger luciferase
activity. These results indicate that most of the ICAM-1 pro-
moter responsiveness (about 75%) to IFI16 is associated to B
sites demonstrating a major role of NF-B as mediator of IFI16
activity.
The residual responsiveness of the minimal pIC135 (AP2)
construct to IFI16 overexpression (about 2.5-fold) (Fig. 4A)
suggested that the Ets transcription factors may also be
involved in the promoter activity regulation by IFI16. To test
this hypothesis, transient transfection assays were performed
with pGL2-ICAM-1, a construct that contains a region of the
ICAM-1 promoter spanning 137 nucleotides upstream from
the transcriptional start site and therefore carrying the two Ets
sites, or the constructs pGL2-ICAM-1mut117, pGL2-ICAM-
FIGURE 3. IFI16 silencing inhibits ICAM-1 induction by IFN-. HUVEC,
untreated (UNT) or infected with the indicated adenoviral vectors for 60 h,
were treated with IFN- (2000 units/ml) or not treated (NT) for 36 h and ana-
lyzed for IFI16 expression by immunoblotting (A) or ICAM-1 expression by
FACS (B). Percentage of positive cells and mean of fluorescence intensity are
reported in each panel. An isotype-matched antibody was used as a control.
Data shown are representative of three independent experiments.
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1mut 97, and pGL2-ICAM-1mut 117–97, in which one or both
the Ets sites were destroyed, respectively (30). As shown in Fig.
4B, inactivation of both Ets sites led to a further reduction of
IFI16-mediated stimulation from2.5-fold of the pGL2-ICAM-1
to 1.4-fold of pGL2-ICAM-1 mut-(117–97), thus suggesting
that Ets factors contribute, albeit weakly, to the IFI16-mediated
regulation of the ICAM-1 promoter. Taken together, our
results indicate that IFI16 transcriptionally activates endothe-
lial genes involved in the inflammatory response and that this
regulation is mediated primarily through activation of the
NF-B complex.
IFI16 Triggers NF-B DNA Binding Activity—The results
derived from functional analysis of the ICAM-1 promoter
prompted us to evaluate if IFI16 activates NF-B. HUVECwere
infected with AdVIFI16 or AdVLacZ, and nuclear extracts pre-
pared for EMSA analysis using NF-B or AP-1 consensus oli-
gonucleotides. As shown in Fig. 5A, nuclear extracts from
mock- or AdVLacZ-infectedHUVEC cells contained low levels
of NF-B activity (upper panel). In contrast, a protein-DNA
complex was observed in HUVEC nuclear extracts infected for
24–48 h with AdVIFI16.When the same nuclear extracts were
incubated with a radiolabeled AP-1 consensus oligonucleotide,
anAP-1DNA-binding complexwas observed inmock-infected
cells, but the levels of this complex were not affected by either
AdVLacZ or AdVIFI16 infection,
suggesting that IFI16 does not influ-
ence AP-1 DNA binding activity
(Fig. 5A, lower panel).
Previous studies from our labora-
tory demonstrated that IFI16 inter-
acts with p53 directly at the DNA
level and increases its binding capa-
bility (11). Addition of anti-IFI16
antibodies inhibited specific p53
DNA binding as shown by super-
shift experiments. To assess if IFI16
interacts with NF-B directly at the
DNA level, antibodies specific for
NF-B subunits or IFI16 were
added to EMSA reactions in super-
shift analysis. As shown in Fig. 5B,
addition of anti-p50 and anti-p-65
antibodies supershifted the protein-
DNA complex from AdVIFI16-in-
fected cells, indicating that NF-B
p50 and p65 proteins are compo-
nents of the IFI16-induced NF-B-
binding complex. In contrast, anti-
IFI16 antibodies did not alter the
mobility of the NF-B complex
indicating that IFI16 was not part of
the protein complex interacting
with the NF-B oligonucleotide.
Furthermore, coimmunoprecipita-
tion analysis with AdVIFI16-in-
fected HUVEC extracts confirmed
the absence of a direct interaction
between IFI16 and NF-B p65 or
p50 proteins (data not shown). Taken together, these results
indicate NF-B as a pivotal transducer of the IFI16 activity in
terms of induction of proinflammatory molecule gene
expression.
To elucidate the functional relevance of IFI16 for NF-B
binding activity induced by IFN-, we next examined whether
ablation of IFI16 can impair NF-B binding upon IFN- treat-
ment. To this end, nuclear extracts were harvested from
HUVEC infected with AdVshRNAIFI16 or AdVshRNASCR in
the presence or absence of IFN-, and gel shift assays were
performed using a NF-B consensus oligonucleotide. As
expected, NF-B binding was induced by IFN- treatment
comparedwith untreated control (Mock, Fig. 5C). By contrast,
the same DNA-protein complex was significantly down-reg-
ulated when HUVEC were infected with AdVshRNAIFI16
before IFN- treatment. Infection with AdVshRNASCR did
not impair NF-B binding, thus demonstrating that IFI16 is
the main mediator of NF-B binding activity upon IFN-
treatment.
IFI16 Overexpression Does Not Activate the IKK Complex but
Triggers Nuclear Translocation of the NF-B Complex—To
clarify how IFI16 triggers NF-B binding to DNA and thus its
transcriptional activity, further experiments were performed to
monitor the expression of NF-B proteins and their nuclear
FIGURE4.Deletionormutationalanalysisofputative IFI16-responsiveelements in the ICAM-1promoter.
A, activation of pIC1352Luc and deletion mutants by IFI16. HUVEC were transfected with the indicated con-
structs and 24 h later infected with AdVIFI16 or AdVLacZ at an m.o.i. of 300. After an additional 36 h, protein
extractswerepreparedandassessed for luciferase activity. Values (S.E.) from three independent experiments
are shown, with data expressed as fold induction of promoter activity as comparedwith the AdVLacZ-infected
cells. B,mutational analysis of putative Ets-responsive elements to IFI16 in the ICAM-1 promoter. HUVEC were
transfected with the indicated constructs and 24 h later infected with AdVIFI16 or AdVLacZ at anm.o.i. of 300.
After an additional 36 h, protein extractswere prepared and assessed for luciferase activity. Values (S.E.) from
three independent experiments are shown, with data expressed as fold induction of promoter activity as
compared with the AdVLacZ-infected cells.
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translocation upon IFI16 overexpression. HUVEC were infected
withAdVLacZorAdVIFI16 for 24, 36, or 48 h, and immunoblot-
ting analysis was performed on whole-cell lysates. As shown
in Fig. 6A, IFI16 overexpression had no effect on the steady-
state levels of the p50 and p65 subunits or the upstream
activating IKK2 kinase, whereas it significantly decreased
the levels of the inhibitory protein IB at all the time points
examined.
The reduced levels of IB in cells overexpressing IFI16
prompted us to investigate whether the upstream IKK complex
was activated by IFI16 thus leading to IB degradation. As
shown in Fig. 6B, activation of the IKK complex (KA) was
detectable only in extracts prepared from HUVEC stimulated
with TNF- (50 ng/ml for 30 min, used as a positive control),
whereas no activation of the complex was detected in IFI16-
overexpressing cells.
To investigate if the reduced levels of IB expression in the
absence of the IKK complex activation were accompanied by
nuclear translocation of the p50-p65 complex, we employed
confocal microscopy to analyze translocation of NF-B phos-
phorylated p65 subunit from the cytoplasm to the nucleus upon
IFI16 overexpression. HUVEC remained either untreated
(mock) or were infected with AdVLacZ or AdVIFI16 before
indirect immunolabeling with anti-pan p65 antibody and
FITC-coupled secondary antibodies. Pan-p65 labeling was
restricted to the cytoplasm in mock and AdVLacZ-infected
cells cultures (Fig. 7). By contrast, AdVIFI16-infected cells
FIGURE 5. IFI16 induces NF-B binding. A, nuclear protein extracts from
HUVEC infectedwith AdVIFI16 or AdVLacZ at anm.o.i. of 300 for the indicated
time points were incubated with radiolabeled oligonucleotides containing
consensus NF-B- (upper panel) or AP-1-binding sites (lower panel). B, super-
shift experiments were performed by addingmonoclonal antibodies against
NF-B p65 or p50 subunits, rabbit anti-IFI16 antibodies, or normal rabbit
serum (NRS) used as a control. C, HUVEC, untreated or infected with the indi-
cated adenoviral vectors for 60 h, were treated with IFN- (2000 units/ml) for
36 h or left untreated. Cells were then lysed, and nuclear extracts were incu-
bated with radiolabeled oligonucleotide containing consensus NF-B-bind-
ing sites. Competition was done with 100-fold excess of cold specific oligo-
nucleotide. Each experiment has been repeated three times, and one
representative experiment is shown.
FIGURE 6. IFI16 does not inhibit IB protein expression through IKK
complex phosphorylation and induces NF-B nuclear translocation.
A, immunoblots of cellular lysates corresponding to AdVIFI16- or AdVLacZ-
infected cells are shown. Cell lysates (20 g/lane), prepared at the indicated
time points, were separated by gel electrophoresis and transferred to Immo-
bilon membranes. The proteins were then probed with anti-IFI16, anti-p50,
anti-p65, anti-IKK2, and anti-IB Abs. The membrane was then incubated
with the appropriate secondary Ab conjugated with horseradish peroxidase
and visualized with ECL kit (Amersham Biosciences). Actin immunodetection
wasperformedas an internal control.B, IFI16doesnot activate the cellular IKK
complex.HUVECwere left untreated, infectedwithAdVIFI16orAdVLacZat an
m.o.i. of 300, or treated with TNF- (50 ng/ml). At the indicated time points,
whole-cell extractswerepreparedandassayed for IKK activity usingGST-IB
as the substrate (KA, kinase assay) (32, 33). Endogenous IKK recovery after
immunoprecipitation was determined by immunoblotting for IKK (IB: IKK).
The experiments were repeated three times, and one representative experi-
ment is shown.
FIGURE 7. IFI16 overexpression results in NF-B nuclear translocation.
HUVEC, left untreated (mock), infected with AdVLacZ or AdVIFI16 at an m.o.i.
of 300 for 24 h, or stimulated with TNF- (50 ng/ml), were analyzed by confo-
cal laser microscopy using an anti-pan-p65 antibody and FITC-coupled sec-
ondary antibodies, or anti-IFI16mAb and Texas Red-coupled secondary anti-
bodies. The experiment were repeated three times, and one representative
experiment is shown.
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revealed clear and intensive nuclear staining, although at a
lower degree compared with the levels obtained by triggering
HUVEC with TNF- used as a positive control. Altogether,
these results suggest that NF-B activation by IFI16 is not
because of the canonical NF-B signaling pathways mediated
by the IKK complex.
IFI16 Transcriptionally Suppresses IB Expression—In
addition to activating p53-dependent transcription, full-length
IFI16 fused to the heterologous GAL4 DNA binding domain
can act as a potent transcriptional repressor when positioned in
proximity to a promoter containing GAL4 DNA elements (37,
38). To further investigate the mechanisms that led to a reduc-
tion of IB steady-state levels by IFI16, we first measured by
real timeRT-PCR IBmRNAexpression.As shown in Fig. 8A,
the IB mRNA levels were significantly decreased (84.7%
and 94.7%, respectively) in cells infected with AdVIFI16 for
24 and 48 h compared with cells
infected with the control AdVLacZ,
suggesting that IFI16 overexpres-
sion reduced steady-state IB
mRNA. To determine whether
IFI16 can directly repress IB
transcription, an indicator plasmid
(p0.4K-pGL3) containing the lucif-
erase reporter gene under the con-
trol of a region corresponding to
400 nucleotides upstream from the
IB transcription start site was
transfected into HUVEC. These
cells were subsequently infected
with either AdVLacZ or AdVIFI16.
As shown in Fig. 8B, IFI16 overex-
pression resulted in a decrease of
more than 90% luciferase activity
when compared with AdVLacZ-in-
fected HUVEC.
In vivo genomic footprinting
identified the promoter-proximal
NF-B/Sp1 transcriptional switch
as an essential component in the
regulation of the IB promoter
(31). To assess how IFI16 down-reg-
ulates IB transcription, the func-
tional roles of the Sp1 and NF-B
sites were evaluated by transient
transfectionwith luciferase reporter
constructs driven by the wild-type
IB promoter (0.4SK) or by mu-
tated versions of the IB pro-
moter. Point mutation of the B1
site of the IB promoter (mutB1)
did not significantly impair IFI16-
induced promoter suppression (Fig.
8C). Strikingly, point mutation of
the Sp1 site (mutSp1) or mutation
of both the B1 and SP1 sites
(mutB1/SP1) relieved suppression
of IB gene expression by IFI16.
Worthy of note, Sp1 mutation caused a significant decrease of
IB promoter activity, consistent with its role in the basic
transcription machinery (39). From these results, we conclude
that a functional Sp1 site is required for suppression of IB
promoter activity by IFI16.
Previous studies showed that IFI16 forms a stable complex
with members of the Sp1/KLF family at a key DNA element
locatedwithin the cytomegalovirusDNApolymerase promoter
(40). To evaluate the IFI16 capability to modulate the interac-
tion of Sp1 with the IB promoter nuclear extracts from
AdVIFI16 or AdVLacZ-infected, cells were analyzed by EMSA.
As shown in Fig. 9A (lanes 1, 2, 4, and 5), the oligonucleotide
spanning the Sp1-binding site formed a major complex with
nuclear extracts from both mock cells or cells infected with
AdVLacZ 12 and 24 h.p.i., respectively. This complex was spe-
cifically competed by a 100-fold higher concentration of the
FIGURE 8. IFI16 inhibits transcription of the IB gene. A, inhibition of IBmRNA synthesis by IFI16. Total
cellular RNAwas extracted fromHUVEC infected with AdVIFI16 or AdVLacZ for the indicated time periods and
reverse-transcribed into cDNA, and the IBmRNA content was measured by real time PCR. The IBmRNA
level standardized to glyceraldehyde-3-phosphate dehydrogenase as an internal control is as shown as per-
centage of AdVLacZ-infected cells. B, inhibition of IB gene promoter by IFI16. HUVEC were transfected with
the wild-type IB promoter (0.4SK-pGL3Luc) and 24 h later infected with AdVIFI16 or AdVLacZ at an m.o.i. of
300. After an additional 48 h, protein extracts were assessed for luciferase activity. Values ( S.E.) from three
independent experiments are shown. C, Sp1 is required for suppression of IB promoter activity by IFI16.
HUVECwere transfectedwith the indicated constructs, and 24 h later infectedwith AdVIFI16 or AdVLacZ at an
m.o.i. of 300. After an additional 48 h, protein extracts were assessed for luciferase activity. Values ( S.E.) from
three independent experiments are shown.
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unlabeled oligonucleotide (Fig. 9A, lane 7) but not by the same
concentration of a mutated oligonucleotide (lane 8). By con-
trast, when nuclear extracts from AdVIFI16-infected HUVEC
were incubated with the labeled Sp1 oligonucleotide, the Sp1
binding activity was significantly reduced at both 12 and
24 h.p.i. (Fig. 9A, lanes 3 and 6) suggesting that IFI16 inhibits
Sp1 DNA binding to the IB promoter. Altogether, these
results demonstrate that suppression of IB transcription by
IFI16 is accompanied by displacement of Sp1-like factors from
its promoter.
To further support this hypothesis, the binding of Sp1 to the
IB promoter in the presence of IFI16, was then analyzed in
vivo byChIP assay. Formaldehyde cross-linked, sonicated chro-
matin fragments from HUVEC infected with AdVIFI16 or
AdVLacZ 24 h earlier were immunoprecipitated with an anti-
Sp1 polyclonal antibody. Then the DNA released from immu-
nocomplexeswas analyzed by quan-
titative real time PCR to detect the
enrichment of the IB promoter
sequences in the immunoprecipi-
tates. The rate of amplification
was verified using cross-linked, not
immunoprecipitated chromatin
(INPUT). The specificity of chro-
matin immunoprecipitation was
determined by using a control unre-
lated antibody. Consistent with
EMSA results, real time PCR analy-
sis of the purified ChIPed DNA
showed indeed that Sp1 antibody
pulled down significantlymore Sp1-
bound IB promoter DNA in
extracts from AdVLacZ-infected
HUVEC compared with those
from AdVIFI16-infected HUVEC
(Fig. 9B). Unrelated, affinity-puri-
fied polyclonal antibodies, used as
negative control, did not immuno-
precipitate the complex containing
the IB promoter (not shown).
Altogether, these findings indicate
that the suppression of IB gene
transcription in the presence of IFI16
is because of an inhibition of the of
Sp1 recruitment to its promoter.
Negative Regulation of IB by
Specific siRNA Results in NF-B
Activation—To examine whether
direct inhibition of IB expression
by specific siRNA resulted in the
same outcome observed with
IFI16, HUVEC were infected with
AdVshIB for 48, 72, or 96 h, and
IB mRNA was analyzed by
quantitative RT-PCR. As shown in
Fig. 10A, IB mRNA levels were
significantly decreased at 96 h.p.i.
compared with mock or AdVsh-
RNASCR-infected cells. These data were also confirmed by
immunoblotting analysis (Fig. 10B).
To verify whether this decrease of IBwas accompanied by
NF-B activation, HUVEC, infected with AdVshRNAIB,
AdVshRNASCR, or AdVIFI16, were analyzed for DNA binding
activity by EMSA. As shown in Fig. 10C, a protein-DNA com-
plexwas observed in nuclear extracts fromHUVEC infected for
96 h with AdVshRNAIB or with AdVIFI16 for 24 h. By con-
trast, a barely retarded complex was observed with nuclear
extracts from HUVEC left untreated (mock) or infected with
AdVshRNASCR. To definitively prove that the retarded com-
plex contained NF-B components, antibodies specific for p65
or p50NF-B subunitswere added to EMSA reactions in super-
shift analysis. As shown in Fig. 9C, addition of anti-p50 and
anti-p-65 antibodies supershifted the protein-DNA complex
from AdVshRNAIB-infected cells, indicating that both
FIGURE 9. Suppression of Sp1 binding to the IB promoter by IFI16. A, nuclear protein extracts from
HUVEC infectedwith AdVIFI16 or AdVLacZ at anm.o.i. of 300 for the indicated timepointswere incubatedwith
a radiolabeled oligonucleotide containing a consensus Sp1-binding site. Competitions were done with 100-
fold excess of cold oligonucleotides, and 1 g of polyclonal antibodies were employed for supershift
experiments. Each experiment has been repeated three times, and one representative experiment is
shown. B, displacement of Sp1 from the IB promoter in AdVIFI16-infected HUVEC was analyzed by ChIP
assay using anti-Sp1 rabbit polyclonal antibodies. Sp1-coprecipitating DNAwas analyzed by quantitative real
time PCR with promoter-specific primers amplifying the IB promoter. An unrelated rabbit polyclonal anti-
serumwas used as control. GenomicDNAobtained fromAdVLacZ- or AdVIFI16-infected cellswas employed to
normalize the DNA subjected to immunoprecipitation (input).
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NF-B p50 and p65 proteins are components of the NF-B-
binding complex induced by IB knockdown.
NF-B activation by IFI16 resulted in the induction of genes,
such as ICAM-1, E-selectin, VCAM-1, and IL-8 all containing
NF-B-binding sites in their promoter region (Fig. 2) (20–22).
To verify if down-regulation of IB followed by NF-B
nuclear translocation and binding to DNA resulted in the same
outcome, HUVEC were infected with AdVshRNAIB or
AdVshRNASCR for 96 h (m.o.i. 1000), mRNA-purified, and
analyzed by real time RT-PCR with appropriate primers. As
shown in Fig. 10D, the levels of mRNA corresponding to
ICAM-1, E-selectin, VCAM-1, and IL8 from AdVshIB-in-
fected HUVEC were increased of 4.8-, 3.2-, 3.5-, and 2.4-fold,
respectively, comparedwith the samemRNA fromAdVshSCR-
infected cells, whereas no induction ofmRNAcorresponding to
PTX-3 was observed. Altogether, these results demonstrate
that IB negative regulation by specific siRNA results in an
outcome similar to that observed with IF16 overexpression.
DISCUSSION
Human IFI16, the interferon-inducible p200 family protein,
modulates various cellular responses as follows: inhibits cell
proliferation, modulates p53-mediated apoptosis, stimulates
senescence in fibroblasts and epithelial cells, plays a role in the
differentiation of CD34/CD38 stem cells, and inhibits tube
morphogenesis of primary endothelial cells (4–6, 38). In this
study, we identify a novel role for IFI16 as inducer of the first
steps of inflammation. The major finding is that IFI16 triggers
ICAM-1 expression by activating theNF-B complex through a
previously unraveled mechanism,
i.e. transcriptional suppression of
IB.
The analysis of gene expression
using DNA microarrays can help to
understand molecular pathways at
the cellular level and can correlate
themwith cellular functions such as
cell proliferation, differentiation,
and apoptosis (41, 42). This analysis
revealed modulation of genes in-
volved in various functions, includ-
ing cell cycle arrest, apoptosis, cell
proliferation, and differentiation.
To validate the gene changes, 6
different genes from the 55 genes
that displayed 0.5- and 2-fold
changes on macroarray analysis
were selected for real time RT-PCR
analysis. Among the various genes,
ICAM-1was up-regulated following
IFI16 overexpression. Together with
the observation that IFI16 expres-
sion is stimulated in HUVEC by
proinflammatory cytokines or oxi-
dative stress (11, 12), this finding
prompted us to investigate if other
proinflammatorymolecules, such as
E-selectin, IL-8, and MCP-1, are
induced aswell. The results obtained by real timeRT-PCR anal-
ysis demonstrated that IFI16 overexpression stimulates indeed
their expression. As such, these studies identify IFI16 as a novel
regulator of endothelial cell proinflammatory gene activation.
IFNs stimulate expression of a large group of immune mod-
ulating genes that play a role both in innate and acquired
immune responses. These genes include chemokines and adhe-
sion molecules that are involved in the recruitment of lympho-
cytes to the site of inflammation and adherence to infected cells
(18, 43). In this context, our observation that IFI16 can stimu-
late ICAM-1, E-selectin, IL-8, andMCP-1 expression is of con-
siderable interest, inasmuch as it now identifies the IFI16 gene
as one of themediators of IFN immunomodulatory activities. In
this study, FACS analysis showed an ICAM-1 expression after
IFN- stimulation of 94% compared with 60% in unstimulated
HUVECs. After transduction with IFI16-specific shRNA, the
stimulated expression of ICAM-1 on the cell surface could be
diminished to 48%.Theminor reduction of ICAM-1 expression
seen upon transduction with scrambled shRNA demonstrates
the specificity of the IFI16 activity and the potency of the
shRNAIFI16 to suppress the expression of the ICAM-1 adhe-
sion molecules in endothelial cells. Taken together, these
results support the hypothesis that silencing of IFI16 expres-
sion in endothelial cells may represent a promising approach
for modulating the induction of proinflammatory molecules by
IFNs, one of the initial steps of inflammatory processes that
precede the onset of autoimmune syndromes.
The process of endothelial activation underlies tight regula-
tory control mechanisms (17). Proinflammatory stimuli target-
FIGURE 10. IB silencing triggers NF-B activation and gene-dependent induction. HUVEC, left
untreated (mock) or infected with AdVsiRNAIB, AdVsiRNASCR, or AdVIFI16, were analyzed for IB
mRNA (A) and protein expression (B) by real time RT-PCR and immunoblotting, respectively. DNA binding
activity was measured using radiolabeled oligonucleotides containing a consensus NF-B binding region
(C). D, real time RT-PCR analysis of RNA expression of the indicated genes. Data shown are representative
of three independent experiments.
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ing the endothelium, such as IFNs, TNF-, IL-1, or bacterial
lipopolysaccharides, elicit activation of intracellular signal
transduction cascades. An important consequence of these
stimuli is the activation of members of the NF-B complex. In
fact, NF-Bwas implicated as the major transcriptional regula-
tor of endothelial adhesionmolecules, including ICAM-1, E-se-
lectin, and chemokines, including IL-8 andMCP-1. Consistent
with these observations IFI16 triggers expression of proinflam-
matory genes by activating the NF-B complex. Until now,
three distinctNF-B-activating pathways have emerged, and all
of them rely on sequentially activated kinases (22–26, 44). Our
studies show that IFI16 is an important regulator of NF-B
activity through an alternative pathway independent fromcyto-
plasmic kinases that lead to the suppression of IB gene tran-
scription and thus allow nuclear translocation of NF-B pro-
teins. This conclusion is based on the following lines of
evidence. First, the levels of IB expression at both protein
andmRNA levels decrease upon IFI16 overexpression. Second,
IFI16 knockdown impairs NF-B binding to DNA triggered by
IFN-. Third, point mutations introduced at the Sp1-binding
sites of the IB promoter and crucial for the basal gene activity
resulted in an impaired IFI16-mediated promoter suppression.
Finally, both EMSA and ChIP assays demonstrated that Sp1
binding to the IB promoter sequences is inhibited by IFI16
overexpression. The mechanisms responsible for the displace-
ment of Sp1 by IFI16 to the IB promoter are unknown at the
moment. IFI16 has been demonstrated to form a stable com-
plex with the cellular transcriptional activators of the Sp1/KLF
factor family at a key DNA element (inverted repeat 1 (IR1))
located within the cytomegalovirus DNApolymerase gene pro-
moter (40). IFI16 was able to repress transcription of a reporter
gene containing wild-type IR1 within the upstream promoter,
whereas mutation of IR1, resulting in loss of binding of the
Sp1-IFI16 complex, caused a loss of IFI16-mediated transcrip-
tional repression (37). In our experimental setting, we could not
demonstrate this type of protein-protein interaction,3 but this
may be due to relative labile binding between IFI16 and Sp1. An
intriguing alternative mechanism may be an indirect interac-
tion in such a way that IFI16 specifically binds to and squelches
certain (co)factors, necessary for the Sp1 transcription factor(s)
to enhance transcription. Our data suggest that the negative
regulation imposed by IFI16 on IB transcription is independ-
ent of alterations in the IKK complex kinetic activity. Support
for these findings comes from the observation that reduction in
IB expression levels by specific siRNA results in the same
outcome (Fig. 10, C and D). Although modulation of IB
expression has been shown previously to be a mechanism
explaining altered NF-B activity (22–27), our study is unique
as we propose a molecular mechanism behind modulated
NF-B activity by which IB protein stability is altered via
gene transcription and is thus independent of alterations in IKK
complex kinetic activity.
The existence of a positive interaction between IFI16 and
NF-B transcription factor may have far reaching implications,
because many genes that play a role in host defense mecha-
nisms contain NF-B elements in their promoter region and
therefore could explain the profound, although largely unex-
plained, harmful effects of IFI16 on the immune system. IFI16
and themouse homologue Ifi202a have indeed been implicated
in the etiology and pathology of systemic lupus erythematosis
(45, 46). High titer anti-IFI16 antibodies were detected in the
sera of 28.7% systemic lupus erythematosus patients but not in
healthy controls. A markedly high frequency of anti-IFI16
autoantibodies was also observed in the sera of another auto-
immune disease, Sjogren syndrome (47). Consistent with these
results we have observed that anti-IFI16 antibodies are present
in the sera of 26.5% patients affected by systemic scleroderma
(16). Interestingly, in accordance with the finding that IFI16
expression is observed in squamous epithelia of the epidermis,
the anti-IFI16 antibodies correlate with the limited cutaneous
form of scleroderma.
In summary, our studies assign to IFI16 a novel role in the
signal transduction pathways regulating the inflammation pro-
cesses and provide a more complete understanding of how
induction of proinflammatory molecules may result in the
onset of autoimmunity.
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